Is it worth offering cardiovascular disease prevention to the elderly?

European Journal of Preventive Cardiology

Volumn 20, Issue 1, 2013, Pages 121-126

  Gohlke, Helmut ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

Blood pressure treatment; exercise in the elderly; influenza vaccination; prevention in the elderly; smoking cessation; statin treatment

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; EXERCISE; HUMAN; HYPERTENSION; INFLUENZA VACCINATION; LIFE EXPECTANCY; MEDITERRANEAN DIET; NUTRITION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK REDUCTION; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE;

EID: 84873908688     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711430384     Document Type: Article

References (30)

1. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation ACSs: a scientific statement for healthcare professionals from the AHA Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007 ; 115: 2549-2569
2. Organisation for Economic Co-operation and Development. OECD health data 2011: http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH-STAT (accessed 6 November 2011).
3. Bartecchi CE, MacKenzie TD, Schrier RW. The human costs of tobacco use. New Engl J Med. 1994 ; 330: 907-912
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Bunell G, Cifkova R, et al. European Guideline on CV Disease Prevention in Clinical Practice. Executive Summary. Eur J Cardiovasc Prev & Rehabilitation. 2007 ; 14 (Suppl 2). E1 - E40
5. Van Domburg RT, Scholte op Reimer W, Hoeks SE, Kappetein AP, Bogers AJJC. Three life-years gained from smoking cessation after CABG: a 30-year follow-up study. Am Heart J. 2008 ; 156: 473-476
6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373: 1849-1860
7. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. Br Med J. 2000 ; 321: 983-986
8. Flather MD, Yusuf S, Kober L, Hall A, Pfeffer M, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000 ; 355: 1575-1581
9. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early CV events after ACSs. Circulation.. 2010 ; 121: 750-758
10. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med Journal. 2004 ; 328: 1519-1527
11. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of CV disease. Circulation. 2008 ; 118: 576-585
12. Gohlke H, Winter M, Karoff M, Held K. CARRISMA: a new tool to improve risk stratification and guidance of patients in CV risk management in primary prevention. Eur J Cardiovasc Prev Rehab. 2007 ; 14: 141-148
13. Algra A, Greving JP. Aspirin in primary prevention: sex and baseline risk matter. Lancet. 2009 ; 373: 1821-1822
14. Afilalo J, Duque G, Steele R, Jukema JW, De Craen AJM, Eisenberg MJ. Statins for secondary prevention in elderly patients. A hierarchical Bayesian meta-analysis. JACC. 2008 ; 51: 37-45
15. De Caterina R, Scarano M, Marfisi RM, Lucisano G, Palma F, Tatasciore A, et al. Cholesterol-lowering interventions and stroke. Insights from a meta-analysis of randomized controlled trials. JACC. 2010 ; 55: 198-211
16. Rahilly-Tierney CR, Lawler EV, Scranton RE, Gaziano JM. Cardiovascular benefit of magnitude of LDL-cholesterol reduction - a comparison of subgroups by age. Circulation. 2009 ; 120: 1491-1497
17. Gränsbo K, Melander O, Wallentin L, Lindbäck J, Stenestrand U, Carlsson J, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. JACC. 2010 ; 55: 1362-1369
18. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005 ; 353: 238-248
19. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 ; 360: 1395-1407
20. investigators GISSI-HF, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 ; 372: 1231-1239
21. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008 ; 358: 1887-1898
22. Shiroma EJ, Lee I-M. Physical activity and cardiovascular health. Lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation. 2010 ; 122: 743-752
23. Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease. A randomized trial. Circulation. 2004 ; 109: 1371-1378
24. Giannuzzi P, Mezzani A, Saner H, Björnstad H, Fioretti P, Mendes M, et al. Physical activity for primary and secondary prevention. Position paper of the working group on cardiac rehabilitation and exercise physiology of the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil. 2003 ; 10: 319-327
25. Piepoli MF, Corrà U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the EACPR. Eur J Cardiovasc Prev Rehabil. 2010 ; 17: 1-17
26. Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. Circulation. 2010 ; 121: 63-70
27. De Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet heart Study. Circulation. 1999 ; 99: 779-785
28. Mitrou PN, Kipnis V, Thiebaut ACM, Reedy J, Subar AF, Wirfalt E, et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population. Results from the NIH-AARP Diet and Health Study. Arch Intern Med. 2007 ; 167: 2461-2468
29. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003 ; 348: 1322-1332
30. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with ACS. Eur Heart J. 2011 ; 32: 1730-1735